321 related articles for article (PubMed ID: 23994249)
21. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways.
Do MT; Kim HG; Khanal T; Choi JH; Kim DH; Jeong TC; Jeong HG
Toxicol Appl Pharmacol; 2013 Sep; 271(2):229-38. PubMed ID: 23707609
[TBL] [Abstract][Full Text] [Related]
22. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response.
Zhong Y; Zhang F; Sun Z; Zhou W; Li ZY; You QD; Guo QL; Hu R
Mol Carcinog; 2013 Oct; 52(10):824-34. PubMed ID: 22593043
[TBL] [Abstract][Full Text] [Related]
23. DJ-1 is involved in the multidrug resistance of SGC7901 gastric cancer cells through PTEN/PI3K/Akt/Nrf2 pathway.
Qiu L; Ma Z; Li X; Deng Y; Duan G; Zhao LE; Xu X; Xiao L; Liu H; Zhu Z; Chen H
Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(11):1202-1214. PubMed ID: 33079995
[TBL] [Abstract][Full Text] [Related]
24. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
25. EGCG inhibits Tat-induced LTR transactivation: role of Nrf2, AKT, AMPK signaling pathway.
Zhang HS; Wu TC; Sang WW; Ruan Z
Life Sci; 2012 May; 90(19-20):747-54. PubMed ID: 22480519
[TBL] [Abstract][Full Text] [Related]
26. Airborne nitro-PAHs induce Nrf2/ARE defense system against oxidative stress and promote inflammatory process by activating PI3K/Akt pathway in A549 cells.
Shang Y; Zhou Q; Wang T; Jiang Y; Zhong Y; Qian G; Zhu T; Qiu X; An J
Toxicol In Vitro; 2017 Oct; 44():66-73. PubMed ID: 28633978
[TBL] [Abstract][Full Text] [Related]
27. Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.
Ozaki K; Kosugi M; Baba N; Fujio K; Sakamoto T; Kimura S; Tanimura S; Kohno M
Biochem Biophys Res Commun; 2010 Jan; 391(4):1610-5. PubMed ID: 20026060
[TBL] [Abstract][Full Text] [Related]
28. Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells.
Mut M; Lule S; Demir O; Kurnaz IA; Vural I
Int J Biochem Cell Biol; 2012 Feb; 44(2):302-10. PubMed ID: 22085529
[TBL] [Abstract][Full Text] [Related]
29. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway.
Shim GS; Manandhar S; Shin DH; Kim TH; Kwak MK
Free Radic Biol Med; 2009 Dec; 47(11):1619-31. PubMed ID: 19751820
[TBL] [Abstract][Full Text] [Related]
30. Nuclear erythroid 2-related factor 2: a novel potential therapeutic target for liver fibrosis.
Yang JJ; Tao H; Huang C; Li J
Food Chem Toxicol; 2013 Sep; 59():421-7. PubMed ID: 23793039
[TBL] [Abstract][Full Text] [Related]
31. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
Su J; Zhang F; Li X; Liu Z
Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
[TBL] [Abstract][Full Text] [Related]
32. (-)-Epigallocatechin-3-gallate Down-regulates Doxorubicin-induced Overexpression of P-glycoprotein Through the Coordinate Inhibition of PI3K/Akt and MEK/ERK Signaling Pathways.
Satonaka H; Ishida K; Takai M; Koide R; Shigemasa R; Ueyama J; Ishikawa T; Hayashi K; Goto H; Wakusawa S
Anticancer Res; 2017 Nov; 37(11):6071-6077. PubMed ID: 29061787
[TBL] [Abstract][Full Text] [Related]
33. Pseudomonas aeruginosa pyocyanin activates NRF2-ARE-mediated transcriptional response via the ROS-EGFR-PI3K-AKT/MEK-ERK MAP kinase signaling in pulmonary epithelial cells.
Xu Y; Duan C; Kuang Z; Hao Y; Jeffries JL; Lau GW
PLoS One; 2013; 8(8):e72528. PubMed ID: 24015256
[TBL] [Abstract][Full Text] [Related]
34. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway.
Xu X; Zhang Y; Li W; Miao H; Zhang H; Zhou Y; Li Z; You Q; Zhao L; Guo Q
Biochem Pharmacol; 2014 Nov; 92(2):220-34. PubMed ID: 25264278
[TBL] [Abstract][Full Text] [Related]
35. Apigenin sensitizes BEL-7402/ADM cells to doxorubicin through inhibiting miR-101/Nrf2 pathway.
Gao AM; Zhang XY; Ke ZP
Oncotarget; 2017 Oct; 8(47):82085-82091. PubMed ID: 29137246
[TBL] [Abstract][Full Text] [Related]
36. Potential roles of PI3K/Akt and Nrf2-Keap1 pathways in regulating hormesis of Z-ligustilide in PC12 cells against oxygen and glucose deprivation.
Qi H; Han Y; Rong J
Neuropharmacology; 2012 Mar; 62(4):1659-70. PubMed ID: 22146407
[TBL] [Abstract][Full Text] [Related]
37. Chrysin Attenuates High Glucose-Induced BMSC Dysfunction via the Activation of the PI3K/AKT/Nrf2 Signaling Pathway.
Li Y; Wang X
Drug Des Devel Ther; 2022; 16():165-182. PubMed ID: 35058687
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells.
Wang XB; Wang SS; Zhang QF; Liu M; Li HL; Liu Y; Wang JN; Zheng F; Guo LY; Xiang JZ
Oncol Rep; 2010 Jan; 23(1):211-5. PubMed ID: 19956884
[TBL] [Abstract][Full Text] [Related]
39. Notoginsenoside R1-mediated neuroprotection involves estrogen receptor-dependent crosstalk between Akt and ERK1/2 pathways: a novel mechanism of Nrf2/ARE signaling activation.
Meng X; Sun G; Ye J; Xu H; Wang H; Sun X
Free Radic Res; 2014 Apr; 48(4):445-60. PubMed ID: 24437944
[TBL] [Abstract][Full Text] [Related]
40. Synergistic Effect of Baicalin and Adriamycin in Resistant HL-60/ADM Leukaemia Cells.
Zheng J; Asakawa T; Chen Y; Zheng Z; Chen B; Lin M; Liu T; Hu J
Cell Physiol Biochem; 2017; 43(1):419-430. PubMed ID: 28869936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
